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Abstract The CA microsatellite repeat marker, D7S522, is
located at the center of a V1000 kb smallest common deleted
region that is lost in many forms of human cancer. It has been
proposed that a putative tumor suppressor gene lies in close
proximity to D7S522, within this smallest common deleted
region. However, the genes located in proximity to D7S522 have
remained elusive. Recently, we identified five independent BAC
clones (V100^200 kb) containing D7S522 and the human genes
encoding caveolins 1 and 2. Here, we present the detailed
organization of the caveolin locus and its relationship to D7S522,
as deduced using a shot-gun sequencing approach. We derived
two adjacent contigs for a total coverage of V250 kb. Analysis
of these contigs reveals that D7S522 is locatedV67 kb upstream
of the caveolin-2 gene and that the caveolin-2 gene is located
V19 kb upstream of the caveolin-1 gene, providing for the first
time a detailed genetic map of this region. Further sequence
analysis reveals many interesting features of the caveolin genes;
these include the intron-exon boundaries and several previously
unrecognized CA repeats that lie within or in close proximity to
the caveolin genes. The first and second exons of both caveolin
genes are embedded within CpG islands. These results suggest
that regulation of caveolin gene expression may be controlled, in
part, by methylation of these CpG regions. In support of this
notion, we show here that the CGs in the 5P promoter region of
the caveolin-1 gene are functionally methylated in two human
breast cancer cell lines (MCF7 and T-47D) that fail to express
the caveolin-1 protein. In contrast, the same CGs in cultured
normal human mammary epithelial cells (NHMECs) are non-
methylated and these cells express high levels of the caveolin-1
protein. Comparison of the human locus with the same locus in
the pufferfish Fugu rubripes reveals that the overall organization
of the caveolin-1/-2 locus is conserved from pufferfish to man. In
conclusion, our current studies provide a systematic basis for
diagnostically evaluating the potential deletion, mutation, or
methylation of the caveolin genes in a variety of human tumors.
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1. Introduction
Deletion of the q31 region of human chromosome 7 has
been implicated in the pathogenesis of many di¡erent forms
of human cancers [1^16]. Such deletions have been detected
using LOH (loss of heterozygosity) analysis, by employing
speci¢c polymorphic CA repeat microsatellite markers that
map to the 7q31.1 region. Among these CA markers,
D7S522 is the most informative. Deletions in the 7q31.1 re-
gion are normally distributed around the D7S522 locus, there-
by de¢ning a smallest common deleted region (SCDR) of
V1000 kb [8,12,14,17]. Interestingly, loss of the D7S522 locus
occurs in a wide variety of human epithelial tumors, including
human primary breast [6], prostate [8,10], ovarian [18], colon
[14], and renal cell carcinomas [11]. In addition, D7S522 spans
a common fragile site, FRA7G, that resides at 7q31.1 [11,19].
Given the association of 7q31.1 and D7S522 LOH with car-
cinogenesis, it has been proposed by numerous laboratories
that an as yet unknown tumor suppressor gene resides within
the 7q31.1 region. However, no genes have been previously
localized to the D7S522 locus.
Recently, we showed that the human genes encoding cav-
eolins 1 and 2 are contained within the same human genomic
BAC clones and co-localize to the q31.1 region of human
chromosome 7, as observed by FISH analysis [20]. Caveolin
family members function as sca¡olding proteins to organize
and concentrate speci¢c lipids (cholesterol and glyco-sphingo-
lipids) and lipid-modi¢ed signaling molecules (Src-like kin-
ases, H-Ras, eNOS and G-proteins) within caveolae mem-
branes [21^23].
CA microsatellite repeat marker analysis of these caveolin
genomic clones indicated that they contain the marker
D7S522, but not other microsatellite repeat markers tested
[20]. The close proximity of caveolins 1 and 2 to the
D7S522 locus was con¢rmed by using a panel of human
STS markers that are known to map in the neighbor-
hood of the D7S522 locus [20]. As it has been shown that
the caveolin-1 protein possesses transformation suppressor
activity [24^27], we proposed that the caveolin-1 gene may
represent the candidate tumor suppressor gene at the
D7S522 locus on human chromosome 7 [20,28]. However,
the detailed organization of the caveolin genes and their
physical distances from each other and from D7S522 is un-
known.
Here, we present the sequence and detailed organization of
the caveolin locus and its relationship to D7S522, as deduced
using a shot-gun sequencing approach. Our results provide for
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the ¢rst time a detailed genetic map of this important chro-
mosomal region.
2. Materials and methods
2.1. Materials
The cDNAs for human caveolin-1 and -2 were as we described
previously [20]. Normal human mammary epithelial cells were ob-
tained from BioWhittaker/Clonetics (Walkersville, MD, USA).
MCF7 (HTB-22) and T-47D (HTB-133) cells were obtained from
ATCC. CpGenome and CpG WIZ kits were purchased from Oncor/
Intergen (Purchase, NY, USA). Anti-caveolin-1 IgG (mAb 2297) were
the generous gift of Dr. Roberto Campos-Gonzalez (Transduction
Laboratories, Lexington, KY, USA). BAC clones containing the mi-
crosatellite marker D7S522 and the genes encoding human caveolin-1
and -2 were as we described previously [20].
2.2. Library construction and shot-gun sequencing approach
We constructed a BAC DNA shot-gun library using high power
ultrasound sonication methods. This was accomplished by generating
a pool of random sized BAC DNA fragments from a single V200 kb
BAC DNA clone. The fragments were end repaired using various
repair enzymes. The fragments were then subsequently blunt end
cloned into the pBluescript SK3 vector. More speci¢cally, several
samples (V5^15 Wg each) of the BAC clone were prepared and
brought to a 50 Wl volume. Each sample was then sonicated for a
speci¢c time interval, i.e. 5 s, 10 s, 15 s, 20 s. Afterwards, V5^10 Wl of
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Fig. 1. Derivation of contigs 1 and 2. Random sequences from a human BAC clone containing D7S522 and the human genes encoding caveo-
lins 1 and 2 (represented here as 6 or s ) were used to identify, join, and order sequences from two other human BAC clones. One BAC
clone RG030H15 (Genbank Accession #AC002066) contained the marker D7S522. The other BAC clone RG011K01 (Genbank Accession
#AC006159) contained eight previously unordered contigs, that we termed A through H. A (21.1 kb); B (24.7 kb); C (33.9); D (38.1 kb); E
(15.6 kb); F (11.6 kb); G (10.1 kb); and H (10.3 kb). These sequences were combined using the program Sequencer to create two new adjacent
contigs representing V250 kb. A: New contig 1. This V190 kb contig combines our shot-gun sequencing with sequences from the entire BAC
clone RG030H15 (Genbank Accession #AC002066) and contigs A, B, and C from BAC clone RG011K01 (Genbank Accession #AC006159).
The positions of D7S522 and the caveolin exons are as indicated. B: New contig 2. This V65 kb contig combines our shot-gun sequencing
with contigs D, E, and F from BAC clone RG011K01 (Genbank Accession #AC006159). However, we were unable to position contigs G and
H within our alignments. The position of caveolin-1/exon 3 is as indicated. The sequences of new contigs 1 and 2 have been deposited in Gen-
bank under accession numbers AJ133269 and AF125348.
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each sonicated sample was analyzed by agarose gel electrophoresis to
determine if any shearing occurred. Next, each of the samples was
pooled and subjected to blunt end repair with mung bean nuclease.
After end repair, the sample was phenol-chloroform extracted and
ethanol precipitated. The entire sample was loaded onto a 0.8% Sea-
Kem GTG agarose gel. The gel region in the range of V1^3 kb was
excised and puri¢ed. Approximately, 10 Wl of this puri¢ed sample was
then blunt end ligated into the pBluescript SK3 vector using T4 DNA
ligase. The ligation mixture was transformed into E. coli (DH10B
cells) and plated out for growth and subsequent blue/white selection.
Clones were robotically picked, ordered into eight 96-well plates, and
DNA was prepared for clone end sequencing using vector primers. In
addition, the eight 96-well plates were compressed into two 384-well
plates and robotically gridded onto ¢lters (see below) that were sub-
sequently hybridized with probes containing D7S522 or the coding
regions of caveolins 1 and 2. Positive clones were retrieved from the
ordered library (stored as glycerol stocks at 380‡C) and subjected to
end and internal sequencing. This approach ensured coverage of
D7S522 and the coding exons of caveolins 1 and 2. Custom robotic
services were provided by Genome Systems, Inc. (St. Louis, MO,
USA).
2.3. Gridding of the shot-gun library
The library consisted of eight microtiter dishes in a 96-well format
housing a total of 768 bacterial clones suspended in a solution com-
prised of LB medium containing glycerol to facilitate storage at
380‡C. These eight blocks were compressed into two 384-well micro-
titer dishes to facilitate robot compatibility. The compression con-
sisted of transferring small amounts of bacteria from the ¢rst four
96-well blocks into one 384-well block (named plate #1 [384-well]) by
means of a 96-pin replicator. Plate #1 [96-well] resides in the A1
quadrant of plate #1 [384-well], plate #2 [96-well] resides in quadrant
A2 of plate #1 [384-well], plate #3 [96-well] resides in the B1 quadrant
of plate #1 [384-well] and plate #4 resides in the B2 quadrant of plate
#1 [384-well]. Plate #2 [384-well] consists of plates 5^8 [96-well] ac-
cording to the same pattern. After the replication was completed,
plates #1 and 2 [384-well] were incubated at 37‡C for 16 h to facilitate
bacterial growth. These plates were then robotically gridded onto a
nylon membrane. This process entails the use of a 384-pin spotting
assembly, which is capable of spotting small amounts of bacteria onto
the membrane in a precise mathematical grid. The plates are spotted
onto the membrane in such a fashion that each bacterial grid, or spot,
may be correlated to an exact plate and well location. This is accom-
plished by double-spotting each plate and well location in a unique
pattern and position which e¡ectively eliminates the occurrence of
false positives. After gridding was completed the membranes were
then lifted onto agar plates and incubated at 37‡C for approximately
14 h, then chemically processed to expose, denature, and ¢x the DNA
of the bacteria on the membrane.
2.4. Western blot analysis
Equal amounts of protein were loaded on an SDS-PAGE gel (12%
acrylamide) and transferred to nitrocellulose. After transfer, nitrocel-
lulose sheets were stained with Ponceau S to visualize protein bands
and subjected to immunoblotting. For immunoblotting, incubation
conditions were as described by the manufacturer (Amersham), except
we supplemented our blocking solution with both 1% BSA and 1%
non-fat dry milk (Carnation).
2.5. Methylation analysis
Bisul¢te treatment of puri¢ed genomic DNA was used to convert
non-methylated cytosines to uracil (U), as per the manufacturer’s
instructions (Oncor/Intergen). Each chemically treated DNA sample
was then ampli¢ed by PCR and directly sequenced using the same
primers used for ampli¢cation. As a consequence, non-methylated
cytosines will appear as thymidines (T) after PCR and DNA sequenc-
ing. Under these conditions, methylated cytosines (5-methylcytosine)
are resistant to modi¢cation and remain as cytosines.
The primer pairs used for PCR ampli¢cation were as follows: for-
ward A, 5P-TGTGTATTTTGtAAAATATGGtTAAttTG-3P ; reverse
A, 5P-CCATCTCTaCCTTAAAACACAT-3P yielding an V350 bp
fragment, as predicted.
Note that bases in lower case were changed from C to t (forward
primer) or from G to a (reverse primer) to re£ect the predicted e¡ects
of bisul¢te treatment on non-methylated cytosines.
3. Results
3.1. Detailed organization of the human caveolin-1 and -2 genes
located near the D7S522 locus (7q31.1)
Recently, we identi¢ed ¢ve independent BAC clones con-
taining the microsatellite marker D7S522 and the genes en-
coding human caveolin-1 and -2 [20]. In order to determine
the detailed organization of the caveolin genes and their phys-
ical distances from each other and from D7S522, we under-
took a shot-gun sequencing approach.
One of these ¢ve clones (clone #1) was physically sheared
to produce random DNA fragments of V1^3 kb, and em-
ployed to construct a library using the vector pBluescript
SK3. Over 700 random clones were picked, assigned an ID
number, and sequenced at the 5P end. In addition, these clones
were robotically gridded onto ¢lters which were then probed
by hybridization with either D7S522 or coding regions of the
caveolin genes (Cav-1/exons 1, 2, and 3; Cav-2/exons 1 and 2).
Approximately six positive clones were obtained for each of
these regions and were then subjected to more extensive se-
quencing using internal primers. This second approach was
taken to ensure coverage of the regions in which we were
most interested.
These individual sequences were assembled into greater
than 50 contigs which were used to perform database
searches. Through this approach, we identi¢ed the sequences
of two human BAC clones that had been deposited. One BAC
clone RG030H15 (Genbank Accession #AC002066) con-
tained the marker D7S522, but not the caveolin genes. The
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Fig. 2. Detailed organization of the human caveolin-1/-2 locus and its relationship to D7S522. Based on contigs 1 and 2 shown in Fig. 1, the
organization of the caveolin-1 and caveolin-2 genes was deduced. The size of each exon and the distance between them is as indicated. Note
that the marker D7S522 is located V67 kb upstream of the caveolin-2 gene and that the caveolin-2 gene is located V19 kb upstream of the
caveolin-1 gene.
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other BAC clone RG011K01 (Genbank Accession
#AC006159) contained eight unordered contigs, some of
which encode regions of the caveolin genes. However, this
second BAC clone apparently lacked the marker D7S522.
In order to resolve this con£ict, we compiled all of our
sequences and the sequences of these two BAC clones and
used the program Sequencer to align them. The results of
this analysis are shown in Fig. 1. Through this approach we
were able to order six of the eight contigs from clone
RG011K01 and to connect them with clone RG030H15. In
most cases, our sequencing results allowed us to connect the
unordered contigs from clone RG011K01 with each other as
well. This alignment produced two new adjacent contigs
(V190 kb and V65 kb), for an overall coverage of
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Table 2
Nine novel CAn microsatellite repeats located in close proximity to the human caveolin genes
Table 1
Intron-exon boundaries for the human caveolin-1 and -2 genes
The DNA sequence upstream or downstream of a given exon is as indicated above.
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Fig. 3. CpG islands are located in close proximity to the ¢rst and second exons of the human caveolin genes. Three CpG islands containing
(A) Cav-2/exon 1, (B) Cav-2/exon 2a, and (C) Cav-1/exon 1 and 2 are shown. The positions of CGs are indicated by boldface uppercase letters
that are underlined. Exon sequences are denoted by boldface lowercase letters and are set apart from adjacent upstream and downstream se-
quences.
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Fig. 4. Methylation of CpG islands in the 5P promoter region of the caveolin-1 gene in breast cancer cell lines that fail to express caveolin-1.
Panel A: Western blot analysis. Using a caveolin-1-speci¢c monoclonal antibody probe (mAb 2297), we analyzed the expression of the caveo-
lin-1 protein in normal human mammary epithelial cells (NHMECs) and two well-studied human breast cancer cell lines (MCF7 and T-47D)
by immunoblotting. Note that caveolin-1 expression is dramatically down-regulated in these breast cancer-derived cell lines, as compared with
the normal human control. Each lane contains equal amounts of total protein. B and C: DNA methylation analysis. Panel B: Genomic DNA
was prepared from each cell type and treated with excess bisul¢te to chemically modify non-methylated cytosines (C) so that they appear as
thymidine (t) after PCR and DNA sequencing. Methylated cytosines are una¡ected by bisul¢te treatment and remain as cytosines (C). The un-
modi¢ed wild-type (WT) sequence is shown above, and the DNA sequences of chemically modi¢ed DNA from a given cell type are shown be-
low. Cytosines are shown in bold uppercase letters; methylated cytosines are boxed and are as indicated (CG in boldface). Note that certain cy-
tosines (C) in the 5P promoter region of the caveolin-1 gene are non-methylated in NHMECs and are converted to thymidines (t); the same
cytosines (C) in MCF7 and T-47D cells were clearly methylated and remain as cytosines (C). Panel C: Chromatogram represented schemati-
cally in panel B.
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V250 kb across this region. Unfortunately, our sequencing
e¡orts to directly join contig 1 and contig 2 were unsuccess-
ful; this may be due to the large distance between them. The
sequences of these two new contigs have been deposited in
Genbank under accession numbers AJ133269 and AF125348.
Contig 1 contains D7S522, the caveolin-2 gene (exons 1, 2a,
and 2b), and a portion of the caveolin-1 gene (exons 1 and 2).
Contig 2, located downstream of contig 1, contains a portion
of the caveolin-1 gene (exon 3). These two contigs were as-
sembled into a single region shown in Fig. 2. Note that
D7S522 is located V67 kb upstream of the caveolin-2 gene
and that the caveolin-2 gene is located V19 kb upstream of
the caveolin-1 gene. In addition, it is interesting to note that
the caveolin-2 gene contains a previously undetected intron
that divides exon 2 into two separate exons. Hence, we have
termed these exons 2a and 2b. These two exons (2a and 2b)
are joined to form a single exon in caveolin-1 and caveolin-3,
suggesting that caveolin-2 may be the precursor for caveolins
1 and 3 through gene duplication.
3.2. Analysis of the sequences surrounding the exons of the
human caveolin-1 and caveolin-2 genes
3.2.1. Intron-exon boundaries. Based on the sequences
compiled in contigs 1 and 2, we deduced the intron-exon
boundaries of the caveolin genes. Sequences upstream and
downstream of a given exon are listed in Table 1. These se-
quences conform well to the known consensus for donor and
acceptor splice junctions. In addition, these sequences will be
extremely useful in searching for mutations within the adja-
cent coding regions of caveolin-1 and caveolin-2.
3.2.2. CA microsatellite repeats. Through sequence analy-
sis of contigs 1 and 2, we identi¢ed nine CA microsatellite
repeats that are present either in close proximity to or within
the caveolin genes, termed CAV-CA1 through 9. These se-
quences are detailed in Table 2. Note that one is located
V1 kb upstream of Cav 2/exon 1, two are located between
Cav-2/exon 2b and Cav-1/exon 1, ¢ve are located between
Cav-1/exon 2 and 3, and one is locatedV11.3 kb downstream
of Cav-1/exon 3. As almost all CA repeats are thought to be
polymorphic, these caveolin-proximal CA repeats will be use-
ful in LOH (loss of heterozygosity) analysis to determine
whether a given region of the caveolin genes is deleted in
human tumors. However, we have not yet checked if these
particular novel CA repeats are indeed polymorphic.
3.2.3. CpG islands. Hypermethylation of cytosine-gua-
nine-rich areas, termed CpG islands, in the 5P promoter region
or the ¢rst exon of a given gene has been suggested as a
potential mechanism for down-regulating the expression of
tumor suppressor genes in certain human tumors, i.e. gene
silencing [29,30]. Thus, we examined contigs 1 and 2 for
CG-rich regions. Interestingly, three CG-rich regions were
identi¢ed and they are all located in close proximity to the
caveolin genes (Fig. 3). More speci¢cally, exons 1 and 2a of
caveolin-2 (Fig. 3A, B) and exons 1 and 2 of caveolin-1 (Fig.
3C) are embedded within these CpG islands. Thus, our studies
identify potential sites for methylation that may regulate cav-
eolin gene expression.
3.3. Methylation of CpG islands in the 5P promoter region of
the caveolin-1 gene in breast cancer cell lines that fail to
express caveolin-1
In order to evaluate whether DNA methylation correlates
with down-regulation of caveolin-1 gene expression, we next
experimentally determined if any of the CGs in the 5P region
of the caveolin-1 gene were functionally methylated.
As a ¢rst step toward this goal, we analyzed the expression
of the caveolin-1 protein in normal human mammary epithe-
lial cells (NHMECs) as compared with caveolin-1 expression
FEBS 21833 2-4-99
Fig. 5. Detailed organization of the caveolin-1/-2 locus in the pu¡er¢sh Fugu rubripes. This diagram is based on the sequence of an V10 kb ge-
nomic clone from Fugu rubripes (Genbank Accession #AJ010316) that contains the genes encoding caveolins 1 and 2. The size of each exon
and the distance between them is as indicated. Note that the sizes of the exons and their organization are highly conserved from pu¡er¢sh to
man (compare with Fig. 2). The positions of three CA repeats located between caveolin-1/exon 2 and 3 are also indicated.
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in two well-studied human breast cancer cell lines (MCF7 and
T-47D). Fig. 4A shows that caveolin-1 expression is dramat-
ically down-regulated in these breast cancer-derived cell lines,
as compared with the normal human control by Western blot
analysis.
We next examined the pattern of caveolin-1 gene methyla-
tion in normal human mammary epithelial cells (NHMECs)
and the corresponding breast cancer cell lines (MCF7 and T-
47D). Genomic DNA prepared from each cell type was
chemically treated with excess bisul¢te to chemically modify
non-methylated cytosines (C) so that they will later appear as
thymidine (T) after PCR and DNA sequencing. Methylated
cytosines are una¡ected by bisul¢te treatment and remain as
cytosines (C) after PCR and DNA sequencing. Using this
approach, we observed that certain CGs in the 5P promoter
region of the caveolin-1 gene are non-methylated in NHMECs
that express the caveolin-1 protein (Fig. 4B, C). In striking
contrast, the same CGs in MCF7 and T-47D cells were clearly
methylated and these cells fail to express caveolin-1 (Fig. 4B,
C). These observations are consistent with the idea that meth-
ylation of the caveolin-1 gene in transformed cells may lead to
a loss of caveolin-1 expression via gene silencing.
3.4. The overall organization of the caveolin-1/-2 locus is con-
served from pu¡er¢sh to man
Through database searches, we identi¢ed a V10 kb ge-
nomic clone from Fugu rubripes (pu¡er¢sh; Genbank Acces-
sion #AJ010316) that contains the genes encoding caveolins 1
and 2. The overall organization of this locus is shown in Fig.
5. Thus, we compared this locus to the corresponding locus
we deduced in humans.
Note that the sizes of the exons and their organization are
highly conserved from pu¡er¢sh to man. However, in the
pu¡er¢sh, the intervening sequences are much smaller. For
example, the human locus encoding caveolins 1 and 2 is
s 60 kb, while the corresponding region in pu¡er¢sh is V9
kb. This is consistent with the observation that the Fugu ru-
bripes genome is approximately 7.5 times smaller than that of
mammals (primarily due to reduced intron size) [31], but with
a similar number of genes (9 kbU7.5 = 67.5 kb).
We also compared the protein sequences of caveolins 1 and
2 from Fugu and man and these alignments are shown in Fig.
6. Note that caveolins from Fugu and man show a high de-
gree of sequence conservation. Caveolin-1 from Fugu is
V84% similar and V74% identical to caveolin-1 from man,
while caveolin-2 from Fugu isV69% similar andV49% iden-
tical to caveolin-2 from man. These results indicate that cav-
eolin-2 can tolerate a higher mutation rate than caveolin-1,
despite the fact that these two genes are located adjacently
within the genome.
4. Discussion
Caveolae are 50^100 nm invaginations of the plasma mem-
brane [32]. It has been proposed that caveolae participate in
tra⁄cking and signal transduction processes [21^23]. Caveo-
lin, a 21^24 kDa integral membrane protein, is a principal
component of caveolae membranes in vivo [33^37]. Caveolin
is only the ¢rst member of a new gene family; as a conse-
quence, caveolin has been re-termed caveolin-1 [38]. Caveolin-
1 is most highly expressed in di¡erentiated cell types such as
epithelial cells, endothelial cells, adipocytes and ¢broblasts
(reviewed in [21,39]). Caveolin-2 shows the same tissue distri-
bution as caveolin-1 [40], while the expression of caveolin-3 is
restricted to muscle cell types [41^43].
It has been proposed that caveolin family members function
as sca¡olding proteins [44] to organize and concentrate spe-
ci¢c lipids (cholesterol and glyco-sphingolipids; [45^47]) and
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Fig. 6. Protein sequence alignments of caveolins 1 and 2 from pu¡er¢sh and man. A: Caveolin-1. Sequences identical to pu¡er¢sh caveolin-1
are boxed. B: Caveolin-2. Sequences identical to pu¡er¢sh caveolin-2 are boxed. The positions of two alternate start sites (thin vertical line),
the membrane spanning domain (thick overline), three conserved cysteines that are site of palmitoylation in mammalian caveolin-1 (asterisks
(*)), and the 12 residues that are invariant from C. elegans to man (uppercase letters above the sequence) are as indicated. Note that the se-
quences for caveolin-1 are more closely related (V74% identical) than the sequences for caveolin-2 (V49% identical).
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lipid-modi¢ed signaling molecules (Src-like kinases, H-Ras,
eNOS and G-proteins; [45,48^52]) within caveolae mem-
branes. In support of this idea, caveolin-1 binding can func-
tionally suppress the GTPase activity of hetero-trimeric G-
proteins and inhibit the kinase activity of Src family tyrosine
kinases, EGF receptor kinases, protein kinase C isoforms, and
components of the p42/44 MAP kinase cascade (MEK and
ERK) through a common caveolin domain, termed the cav-
eolin-sca¡olding domain [26,48^50,53^56].
Several independent lines of evidence are consistent with the
idea that caveolin-1 functions as a tumor suppressor gene: (i)
caveolin-1 mRNA and protein expression are down-regulated
during cell transformation of cultured NIH 3T3 cells, in trans-
genic mouse models of breast cancer, and in cell lines derived
from human breast cancers [24^27,57] ; (ii) recombinant ex-
pression of caveolin-1 in transformed NIH 3T3 cells or cell
lines derived from human breast cancers can suppress their
transformed phenotype, such as anchorage-independent
growth in soft agar [25,27]; and (iii) selective down-regulation
of caveolin-1 expression using an anti-sense approach is su⁄-
cient to promote anchorage-independent growth in soft agar,
drive tumor formation in nude mice, and hyperactivate the
p42/44 MAP kinase cascade in otherwise normal NIH 3T3
cells [58].
Independently, recent genetic evidence shows that the cav-
eolin-1 and -2 genes are co-localized to a suspected tumor
suppressor locus in mice (6-A2) and humans (7q31.1/
D7S522) [20,28,59]. In addition, the human caveolin-1 and
-2 genes map at a maximum distance of V100^200 kb from
D7S522 [20]. This region (D7S522) is the center of the small-
est common deleted region (SCDR), which harbors a pre-
sumed tumor suppressor gene [8,12,14,17]. However, the de-
tailed organization of the caveolin genes and their exact
physical distances from the D7S522 locus and from each other
has remained unknown.
Here, through a shot-gun sequencing approach, we derived
two adjacent contigs (V190 and V65 kb) that contain both
D7S522 and the caveolin genes, for a total coverage of V250
kb across this genomic region. Detailed analysis of these con-
tigs shows that D7S522 is located V67 kb upstream of the
caveolin-2 gene and that the caveolin-2 gene is located V19
kb upstream of the caveolin-1 gene. As such, the human genes
encoding caveolins 1 and 2 are the closest known genes in the
immediate vicinity of the D7S522 locus. Sequence analysis of
this region reveals (i) the intron-exon boundaries of the cav-
eolin genes, (ii) previously unrecognized CA repeats that lie
within or close to the caveolin genes, and (iii) that the ¢rst
and second exons of both caveolin genes are embedded within
CpG islands, i.e. potential sites for regulating gene expression
by methylation. This critical genetic information will allow us
and others to systematically evaluate whether the human cav-
eolin genes are potentially deleted, mutated, or silenced by
methylation during human tumor formation or metastasis.
In order to examine if caveolin-proximal CpG islands are
functionally methylated in vivo, we analyzed the methylation
status of a CpG island in the 5P promoter region of the cav-
eolin-1 gene in a variety of cultured cells. We observed that
this CpG region is non-methylated in cultured normal human
mammary epithelial cells (NHMECs) that express high levels
of the caveolin-1 protein product. In contrast, we found that
this CpG region is clearly methylated in two highly trans-
formed human breast cancer cell lines (MCF7 and T-47D)
that fail to express the caveolin-1 protein. In this regard, it
is interesting to note that recombinant expression of caveolin-
1 in T-47D cells is su⁄cient to revert their transformed phe-
notype, preventing their anchorage-independent growth in
soft agar [27]. These ¢ndings are consistent with the general
observation that methylation of CpG islands in the 5P pro-
moter region of a given tumor suppressor gene (p16, p15,
VHL and E-cadherin) strictly correlates with down-regulation
of their expression [29,30]. This type of gene silencing high-
lights an important alternative mechanism for inactivation of
tumor suppressor genes, i.e. one that does not require point
mutation or deletion of a speci¢c gene [29,30].
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